Press Releases

New data to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2022 in New Orleans show that patients with non-small cell lung cancer (NSCLC) who received the targeted therapy sotorasib experienced extended survival and good quality of life. Grace Dy, MD, will present the longest-term data available from the multicenter CodeBreaK100 clinical trial in a plenary presentation today.

Two Roswell Park oncologists will discuss promising strategies for making breakthrough immunotherapies work for more patients at the annual meeting of the American Association for Cancer Research (AACR) in New Orleans, Louisiana, on Monday, April 11. Both presentations report findings from clinical trials that advance a novel immunotherapy platform in development at Roswell Park.

Dozens of cancer specialists at Roswell Park Comprehensive Cancer Center have been invited to present their latest advances in cancer research at the annual meeting of the American Association for Cancer Research (AACR), which will take place in New Orleans, Louisiana, from April 8 to 13.

Roswell Park Comprehensive Cancer Center is proud to announce its designation as an LGBTQ+ Healthcare Equality Leader on the Human Rights Campaign Foundation’s Healthcare Equality Index (HEI) 2022.

Congressman Brian Higgins (NY-26), Co-Chair of the House Cancer Caucus, joined Roswell Park CEO Dr. Candace Johnson to announce $1.5 million in federal funding awarded to Roswell Park Comprehensive Cancer Center. Secured by Congressman Higgins as part of the fiscal year 2022 budget recently passed by Congress and signed into law, this funding will support the upgrade of computed tomography (CT) equipment including the purchase of a new CT scanner, as well as efforts to promote and increase lung cancer screenings, particularly those in underserved communities. 

Transportation barriers, including access to public transportation or a personal vehicle, disproportionately affect cancer survivors, particularly if they are young, uninsured or live below the poverty line, according to results of a study published today in JAMA Oncology.

A multidisciplinary team of researchers from Roswell Park Comprehensive Cancer Center and Kaiser Permanente Northern California have identified the first pharmacogenomic marker for anthracyclines and HER2-targeting drugs, two commonly used breast cancer chemotherapies. The results of the large genetic analysis were published today in NPJ Breast Cancer.